Vaccines

June 16, 2022

VUMC research aids approval of COVID-19 vaccine for young children

The U.S. Food and Drug Administration is expected to authorize Pfizer and Moderna’s COVID-19 vaccines for children as young as 6 months old as early as tomorrow, following the unanimous recommendation by an FDA advisory panel on Wednesday.

By Bill Snyder
June 1, 2022

RSV vaccine trial enrolling 6- to 24-months-old children

By VUMC News and Communications
May 19, 2022

Panel considers ways to improve vaccine readiness, restore trust

A recent Ethics Grand Rounds, sponsored by the Vanderbilt Center for Biomedical Ethics and Society, explored potential ways to overcome vaccine readiness and restore trust in health care providers.

By Bill Snyder
May 12, 2022

VUMC-led study finds Moderna COVID vaccine safe and effective for children

By Bill Snyder
April 13, 2022

Additional COVID vaccine helps protect transplant patients

Additional booster doses of vaccine against COVID-19 are particularly important for those who are immunosuppressed, namely those who have had solid organ transplants, a new study shows.

By Nancy Humphrey
April 13, 2022

Volunteering for vaccine research a family affair

By Kristin Smart
April 7, 2022

Study explores parents’ reluctance to flu, COVID vaccines for children

Vanderbilt research found parents who are reluctant to vaccinate their children against the flu are more than five times as likely to decline the COVID-19 vaccine for their children.
By Jessica Pasley
March 31, 2022

Crowe receives national award for COVID antibody research

Vanderbilt's James Crowe Jr., MD, and Michel Nussenzweig, MD, PhD, of The Rockefeller University, have been jointly awarded the 2022 Harrington Prize for Innovation in Medicine for “groundbreaking work” that enabled the use of human antibodies to treat COVID-19.
By Bill Snyder
March 10, 2022

Technique hastens COVID-19 antibody discovery

Optimization of a technique developed at Vanderbilt University Medical Center enables rapid and efficient identification of neutralizing monoclonal antibodies against the virus that causes COVID-19.
By Bill Snyder
March 3, 2022

COVID-19: two years of challenges, lessons, victories

Two years ago this week, the cataclysmic coronavirus known as SARS-CoV-2 arrived in Middle Tennessee.
By Bill Snyder
February 17, 2022

Pandemic leads to broader use of monoclonal antibodies

Antiviral drugs and coronavirus-fighting monoclonal antibodies, including those discovered at Vanderbilt University Medical Center, remain crucially important in the continuing fight against COVID-19.
By Bill Snyder
February 9, 2022

Vanderbilt and CDC research shows third vaccine dose key to preventing omicron hospitalization

Vanderbilt research shows that two doses of an mRNA COVID-19 vaccine result in lower effectiveness for preventing hospitalization for the omicron variant than previous variants. However, importantly, a third (“booster”) vaccine dose significantly improves protection against omicron hospitalization up to 86%.
By Kristin Smart
January 24, 2022

Vanderbilt recruiting children to study allergic responses to COVID-19 mRNA vaccines

Vanderbilt is conducting a clinical trial to determine risk and mechanisms of allergic reactions to COVID-19 Pfizer-BioNTech mRNA vaccine among children.
By Jessica Pasley
1 2 3 4 5 6 … 14